Search Results
Your search for The ASCO matches 21144 pages
Showing 7801 - 7850Randall A. Oyer, MD, Named President of the Association of Community Cancer Centers
At the Association of Community Cancer Centers (ACCC) 46th Annual Meeting & Cancer Center Business Summit, held March 4–6 in Washington, DC, Randall A. Oyer, MD, was named ACCC President for 2020–2021. Dr. Oyer announced that the theme of his presidency will be “Community Oncology Can Close the ...
International Association for the Study of Lung Cancer Names Research Award After Fred R. Hirsch, MD, PhD
The International Association for the Study of Lung Cancer (IASLC) recently announced it is naming the Translational Research Lectureship Award after longtime member and former IASLC Chief Executive Officer Fred R. Hirsch, MD, PhD. The award, which was previously named after Adi Gazdar, MD, who...
Charles Sawyers, MD, Receives Knudson Award in Cancer Genetics
The National Cancer Institute (NCI) has named Charles Sawyers, MD, as the recipient of the 2020 Alfred G. Knudson Award in Cancer Genetics. Dr. Sawyers is Chair of the Human Oncology and Pathogenesis Program and the Marie-Josée and Henry R. Kravis Chair at Memorial Sloan Kettering Cancer Center, as ...
Memorial Sloan Kettering Announces Two New Appointments
Memorial Sloan Kettering Cancer Center (MSK) recently appointed Sergio Giralt, MD, and Miguel-Angel Perales, MD, as Deputy Division Head of the Division of Hematologic Malignancies and Chief of the Adult Bone Marrow Transplant Service, respectively. Dr. Giralt: New Roles and Old Former Chief of...
Neratinib Combined With Capecitabine in Previously Treated Advanced HER2-Positive Breast Cancer
On February 25, 2020, neratinib (Nerlynx) was approved for use in combination with capecitabine for treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti–HER2-based regimens in the metastatic setting.1,2 Supporting Efficacy ...
Cancer During Pregnancy: Whose Moral Compass to Follow?
As has often been written, “Cancer is the greatest equalizer.” It tends to strike its victims regardless of their financial status. In low- and middle-income countries, however, the impact of poverty on the treatment of cancer is strikingly conspicuous. It is the major catalyst for delay in seeking ...
How Exercise Oncology Can Improve Cancer Outcome and Survivorship
Researchers from the American College of Sports Medicine (ACSM) recently reviewed hundreds of epidemiologic studies on the link between physical activity and both cancer risk and cancer mortality. A subsequent analysis of the findings by a panel of experts representing 17 partner organizations,...
Oncologists on the Front Lines of COVID‑19
Coronavirus disease 2019 (COVID-19) is dramatically affecting health-care systems. This is the first in a series of interviews The ASCO Post will conduct with oncologists, to learn what they and their cancer centers are doing to deal with the crisis. In this article, we talk with John Cole, MD, a...
Patients With Certain Cancers May Be at a Higher Risk for Atrial Fibrillation
People with a history of cancer have an over twofold risk of developing atrial fibrillation, the most common heart rhythm disorder, compared to the general population, according to research presented at the American College of Cardiology’s Annual Scientific Session (Abstract 1216-235). In...
A Message From the FDA OCE for Patients With Cancer and Health-Care Providers on COVID-19
On March 23, the U.S. Food and Drug Administration (FDA) Oncology Center of Excellence (OCE) issued the following statement: The FDA OCE recognizes that patients with cancer constitute a vulnerable population at risk of contracting the coronavirus disease (COVID-19). While everyone’s daily lives...
Phase III JAVELIN Gastric 100 Trial Finds No Survival Benefit for Maintenance Avelumab
In the phase III JAVELIN Gastric 100 trial, a strategy called “switch maintenance” with the immune checkpoint inhibitor avelumab after 12 weeks of first-line induction chemotherapy did not statistically improve overall survival for treatment-naive patients with HER2-negative advanced gastric or...
Pembrolizumab in MSI-H and CPS ≥ 10 Advanced Gastric or Gastroesophageal Junction Cancer: Subanalysis of KEYNOTE-059, -061, and -062
The survival benefit of pembrolizumab in advanced gastric/gastroesophageal junction cancer with microsatellite instability–high (MSI-H) tumors or a combined positive score (CPS) ≥ 10 was established in post hoc subanalysis of three KEYNOTE trials. Findings were presented at the 2020...
Expert Point of View: Richard L. Schilsky, MD, FACP, FSCT, FASCO
Richard L. Schilsky, MD, FACP, FSCT, FASCO, Chief Medical Officer and Executive Vice President of ASCO, called the 74% response rate to cisplatin/gemcitabine “remarkable.” “What’s impressive to me is the high response rate, as well as the progression-free and overall survival data—these data are...
Cisplatin/Gemcitabine Alone and With Veliparib in BRCA-Mutated Advanced Pancreatic Cancer
In patients with pancreatic ductal adenocarcinoma and a germline BRCA/PALB2 mutation, first-line therapy with cisplatin plus gemcitabine yielded high response rates and encouraging survival, according to Eileen M. O’Reilly, MD, of Memorial Sloan Kettering Cancer Center, who presented the findings...
Genetic Counseling and Testing of Patients With Pancreatic Cancer
Routine genetic counseling and multigene testing of patients with pancreatic cancer result in the detection of mutations that are actionable, not only for patients, but also for at-risk family members. At the Dana-Farber Cancer Institute in Boston, the use of a systemized, automated referral system ...
Maintenance Olaparib in BRCA1/2-Positive Pancreatic Cancer Yields Improved Progression-Free Survival, Preserves Quality of Life
Health-related quality of life was preserved during maintenance olaparib in patients with BRCA 1/2-positive pancreatic cancer, as evidenced by a low symptom burden over time.1 POLO investigators reported their findings in posters presented at the 2020 Gastrointestinal Cancers Symposium. Other...
Expert Point of View: Christopher M. Booth, MD
Christopher M. Booth, MD, the invited discussant of the BEACON CRC quality-of-life findings, applauded the investigators for choosing overall survival and quality of life as endpoints in a trial that benefits a “vulnerable patient population with unmet needs.” Patients with BRAF-mutated metastatic...
Mature Follow-up of BEACON CRC Study Reports Quality-of-Life Measures and Survival Outcomes
For patients with previously treated metastatic colorectal cancer harboring BRAF V600E mutations, the phase III BEACON CRC study showed the benefit for combining two or three targeted agents vs the standard of care.1 With further follow-up, the study has now also shown a benefit for the triplet and ...
TAPUR Basket Study: Biomarker-Driven Treatment Strategies Yield Benefits in Colorectal Cancer
Positive findings on the potential benefit of molecularly targeted drugs in patients with advanced colorectal cancer were presented at the 2020 Gastrointestinal Cancers Symposium, validating the purpose of ASCO’s Targeted Agent and Profiling Utilization Registry (TAPUR) study.1-3 TAPUR, the first...
Expert Point of View: A. Craig Lockhart, MD
A. Craig Lockhart, MD, Professor of Medicine, University of Miami Sylvester Comprehensive Cancer Center, applauded the study for making patient-reported outcomes a prespecified endpoint and described the value of having this information. Dr. Lockhart was the invited discussant. “The U.S. Food and...
IMbrave150 Prespecified Analysis Adds Improved Quality-of-Life to Survival Benefits Reaped With Atezolizumab Plus Bevacizumab
New findings from a prespecified analysis of the pivotal IMbrave150 trial revealed improved quality of life for patients with advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab in the first-line setting. These results were reported by Peter R. Galle, MD, at the 2020...
Conference Highlights From the 2020 Gastrointestinal Cancers Symposium
This past January, the 2020 Gastrointestinal Cancers Symposium was held in San Francisco. More than 3,600 individuals attended and more than 900 abstracts and posters were presented. Among the highlights presented at the meeting and reported in the pages of The ASCO Post, several studies in...
A Discussion About CAR T-Cell Therapy for Multiple Myeloma and Lymphoma
Dr. Armitage discusses the role of CAR T-cell therapy in the management of multiple myeloma and lymphoma in a conversation with his colleagues Dr. Holstein and Dr. Lunning.
A Case of Diffuse Large B-Cell Lymphoma
Dr. Armitage presents a case and asks Dr. Lunning to describe how he would treat this patient. The patient is a 52-year-old man who found a neck mass himself. He went to his doctor and was prescribed antibiotics. When the antibiotics failed to impact the mass, a biopsy was performed and a diagnosis ...
A Case of Relapsed/Refractory Multiple Myeloma
Dr. Armitage presents a case and asks Dr. Holstein to comment about her approach to treatment. The patient is be a 59-year-old man who had presented with symptomatic myeloma with bone pain and he was feeling unwell. He had bone lesions on images. He was anemic. This all happened 2 years ago. He was ...
A Case of Relapsed/Refractory Hodgkin Lymphoma
Dr. Armitage presents a case and asks Dr. Lunning to describe how he would treat this patient. The patient is a 25-year-old man with a diagnosis of stage III nodular sclerosing Hodgkin lymphoma. His disease went into complete remission when the patient was treated with ABVD and he was well. One...
A Case of Smoldering Myeloma
In this episode, Dr. Armitage presents a case and asks Dr. Holstein to comment on her approach to treatment of this individual. The patient is a 65-year-old man who was referred because of a monoclonal protein found in his blood. The patient was asymptomatic. He had a normal exam. He had an IgG...
Expert Point of View: Charles G. Drake, MD, PhD
“This is a great study. It is one of the largest series of prostate-specific membrane antigen (PSMA) scans and covers many patient scenarios, including initial staging, restaging after surgery or radiation or hormonal therapy, and re-imaging in advanced disease,” said Charles G. Drake, MD, PhD, a...
PSMA PET/CT May Have Major Impact on Treatment of Patients With Prostate Cancer
Prostate cancer experts speaking at the 2020 Genitourinary Cancers Symposium alluded to the fact that prostate-specific membrane antigen (PSMA) positron-emission tomography (PET)/computed tomography (CT) scanning is more sensitive than conventional imaging for the detection of occult lesions in men ...
Trends in Deaths From Cutaneous Melanoma in the United States
Recent treatment advances in metastatic melanoma resulted in reductions in population-level mortality from the disease, according to a study published by Polsky et al in the American Journal of Public Health. Methods Researchers analyzed new cases and deaths from melanoma from nine U.S....
Digital Breast Tomosynthesis vs Digital Mammography Outcomes: Comparison Over 5 Years
A new study published by Conant et al in the journal Radiology found that the advantages of digital breast tomosynthesis over digital mammography, including increased cancer detection and fewer false-positive findings, are maintained over multiple years and rounds of screening. In addition,...
COVID-19 May Remain Stable for Hours to Days in Aerosols and on Surfaces
The virus that causes coronavirus disease 2019 (COVID-19) is stable for several hours to days in aerosols and on surfaces, according to a new study published as a research letter in The New England Journal of Medicine. A team of researchers from the National Institutes of Health (NIH); the Centers ...
Cancer Incidence and Survivorship in Transgender Patients
The first-ever population-based study of cancer prevalence in transgender people was recently published by Boehmer et al in the journal Cancer. The authors of the report estimate that 62,530 of the nearly 17 million cancer survivors in the United States are transgender. Methods The researchers used ...
Spring 2020 ABIM Maintenance of Certification Exams Canceled
The American Board of Internal Medicine (ABIM) has announced that all spring 2020 maintenance of certification (MOC) assessment administrations are canceled in light of the COVID-19 pandemic. They issued the following communication: As frontline health-care professionals, many board-certified...
Continuous Coverage of COVID-19
The staff of The ASCO Post recognizes the steady flow of news on the novel coronavirus, or COVID-19. Here, we've compiled a list of links to articles and resources on the COVID-19 pandemic. If you have a report you'd like to share, please e-mail it to us at editor@ascopost.com. Direct From ASCO:...
Strategies for Protecting Patients and Health-Care Providers Against COVID-19
For Patients Patients undergoing active treatment for cancer and cancer survivors may be at increased risk of becoming infected with the coronavirus because of their compromised immune system and their susceptibility to other illnesses. ASCO has developed information on Cancer.Net on how patients...
How COVID-19 Is Affecting the Oncology Community
Over the past month, medical societies worldwide have been monitoring the escalating outbreak of the novel coronavirus and its effect on international and domestic travel and making difficult decisions to cancel or postpone their scientific conferences or make them available digitally. On March...
Selected Abstracts on Novel Treatments in Colon, Hepatocellular, and Biliary Tract Cancers
The ASCO Post has reported on the pivotal trials presented at the 2020 Gastrointestinal Cancers Symposium in several issues. Featured here are the findings of several additional abstracts worthy of mention. Intermittent Oxaliplatin in Stage II or III Colon Cancer As adjuvant treatment for stage II...
Are Younger Cancer Survivors More Susceptible to Financial and Food-Related Anxieties?
New research from the American Cancer Society published by Zheng et al in JNCCN–Journal of the National Comprehensive Cancer Network found that younger cancer survivors are more likely to experience significant financial strain for daily living necessities—such as food, housing, and monthly...
Risk of Cervical Cancer With Different Types of Intrauterine Devices
Patients who used copper intrauterine devices (IUDs) were found to have a lower risk of high-grade cervical neoplasms vs users of the levonorgestrel-releasing intrauterine system, according to a study published by Spotnitz et al in the journal Obstetrics & Gynecology. The study notes that more...
New ASCO Guideline Highlights the Management of Male Breast Cancer
THE ANNUAL INCIDENCE of male breast cancer in the United States is dwarfed by the rate among women. Yet, for the estimated 2,670 men who will be diagnosed with breast cancer this year, life-extending and life-enhancing treatments are crucial.1 To help reduce knowledge gaps and improve mortality and ...
Study Focuses on Role of Microbes in Pancreatic Cancer
Although bacteria are predominant in the gastrointestinal tract, they also reside on and in other parts of the body, including some unexpected places, such as malignant tumors. There are numerous reports of this phenomenon, but most have not identified a functional role for the microbes. In the...
FDA Pipeline: Breakthrough Therapy for NSCLC With Specific Mutation, Approval of Test for Cervical Cancer, and More
Over the past week, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to a bispecific antibody for the treatment of patients with metastatic non–small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations; granted approval to a test for human...
Colorectal Cancer Statistics 2020 Published
The burden of colorectal cancer is shifting to younger individuals as incidence increases in young adults and declines in older age groups, according to Colorectal Cancer Statistics 2020. The median age of diagnosis dropped from 72 in 2001–2002 to 66 in 2015–2016. This finding and other data were...
Annual Report to the Nation on the Status of Cancer Released
The Annual Report to the Nation on the Status of Cancer has found that cancer death rates continued to decline from 2001 to 2017 in the United States for all cancer sites combined. The report was published by Hensley et al in the journal Cancer. The annual report is a collaborative effort among the ...
Pulmonary Pathology of the Novel Coronavirus in Two Patients With Lung Cancer
We’ll begin this week by discussing an article that described the pulmonary pathology of the novel coronavirus, or COVID-19, which was found coincidentally in two patients undergoing surgery for lung cancer. We’ll also update you as to upcoming oncology meetings that have been canceled due to...
HAPLO2019: Advances in Haploidentical Transplantation and Other Novel Cellular Therapies
Now in its seventh year, the Haploidentical Transplant Symposium (HAPLO) continues to explore advances in haploidentical and other novel cellular therapies. The most recent of these meetings—HAPLO2019—met in Orlando, Florida, 2 days before the start of the 2019 American Society of Hematology (ASH)...
Receipt of Adjuvant vs Neoadjuvant Chemotherapy and Start of Treatment in Patients With Breast Cancer
Research published by Melchior et al in Cancer Medicine has indicated that starting chemotherapy before surgery does not expedite the start or completion of treatment for breast cancer vs performing surgery first. “Increasingly, patients are given [neoadjuvant] chemotherapy…This is done for breast ...
Five-Year Survival for Cancers in Adolescents and Young Adults: 4-Decade Analysis
The 5-year survival rate for adolescents and young adults with cancer has significantly improved from 1975 to 2005 in the United States overall, but this was not the case for all types of cancer, according to a report published by Anderson et al in the Journal of the National Cancer Institute. “We ...
FDA Approves Nivolumab/Ipilimumab for Pretreated Patients With Hepatocellular Carcinoma
On March 10, the U.S. Food and Drug Administration (FDA) granted accelerated approval to the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) for patients with hepatocellular carcinoma who have been previously treated with sorafenib. CheckMate 040 Efficacy of the combination was...
